{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:07:17Z","timestamp":1747714037436,"version":"3.40.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T00:00:00Z","timestamp":1424304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"DOI":"10.1007\/s11095-015-1641-2","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T23:12:22Z","timestamp":1424214742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prediction of Drug Transfer into Milk Considering Breast Cancer Resistance Protein (BCRP)-Mediated Transport"],"prefix":"10.1007","author":[{"given":"Naoki","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousei","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ikebuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hisaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,19]]},"reference":[{"key":"1641_CR1","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.socscimed.2007.03.008","volume":"64","author":"R Flacking","year":"2007","unstructured":"Flacking R, Ewald U, Starrin B. \u201cI wanted to do a good job\u201d: experiences of \u2018becoming a mother\u2019 and breastfeeding in mothers of very preterm infants after discharge from a neonatal unit. Soc Sci Med. 2007;64:2405\u201316.","journal-title":"Soc Sci Med"},{"key":"1641_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(03)13811-1","volume":"362","author":"G Jones","year":"2003","unstructured":"Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS. How many child deaths can we prevent this year? Lancet. 2003;362:65\u201371.","journal-title":"Lancet"},{"key":"1641_CR3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.earlhumdev.2010.08.005","volume":"86","author":"MS Kramer","year":"2010","unstructured":"Kramer MS. \u201cBreast is best\u201d: the evidence. Early Hum Dev. 2010;86:729\u201332.","journal-title":"Early Hum Dev"},{"key":"1641_CR4","first-page":"594","volume":"10","author":"PO Anderson","year":"1991","unstructured":"Anderson PO. Drug use during breast-feeding. Clin Pharm. 1991;10:594\u2013624.","journal-title":"Clin Pharm"},{"key":"1641_CR5","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1136\/bmj.290.6481.1588-a","volume":"290","author":"I Matheson","year":"1985","unstructured":"Matheson I. Drugs taken by mothers in the puerperium. Br Med J (Clin Res Ed). 1985;290:1588\u20139.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1641_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00003088-199018020-00005","volume":"18","author":"HC Atkinson","year":"1990","unstructured":"Atkinson HC, Begg EJ. Prediction of drug distribution into human milk from physicochemical characteristics. Clin Pharmacokinet. 1990;18:151\u201367.","journal-title":"Clin Pharmacokinet"},{"key":"1641_CR7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2125.1992.tb04077.x","volume":"33","author":"EJ Begg","year":"1992","unstructured":"Begg EJ, Atkinson HC, Duffull SB. Prospective evaluation of a model for the prediction of milk: plasma drug concentrations from physicochemical characteristics. Br J Clin Pharmacol. 1992;33:501\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"1641_CR8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0169-409X(03)00032-2","volume":"55","author":"JC Fleishaker","year":"2003","unstructured":"Fleishaker JC. Models and methods for predicting drug transfer into human milk. Adv Drug Deliv Rev. 2003;55:643\u201352.","journal-title":"Adv Drug Deliv Rev"},{"key":"1641_CR9","doi-asserted-by":"crossref","unstructured":"Rasmussen F. Mammary excretion of benzylpenicillin, erythromycin, and penethamate hydroiodide. Acta Pharmacol Toxicol (Copenh). 1959;16:194\u2013200.","DOI":"10.1111\/j.1600-0773.1959.tb01201.x"},{"key":"1641_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2125.1995.tb04555.x","volume":"40","author":"LJ Notarianni","year":"1995","unstructured":"Notarianni LJ, Belk D, Aird SA, Bennett PN. An in vitro technique for the rapid determination of drug entry into breast milk. Br J Clin Pharmacol. 1995;40:333\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"1641_CR11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jps.2600760302","volume":"76","author":"JC Fleishaker","year":"1987","unstructured":"Fleishaker JC, Desai N, McNamara PJ. Factors affecting the milk-to-plasma drug concentration ratio in lactating women: physical interactions with protein and fat. J Pharm Sci. 1987;76:189\u201393.","journal-title":"J Pharm Sci"},{"key":"1641_CR12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1592\/phco.21.7.669.34574","volume":"21","author":"PM Gerk","year":"2001","unstructured":"Gerk PM, Kuhn RJ, Desai NS, McNamara PJ. Active transport of nitrofurantoin into human milk. Pharmacotherapy. 2001;21:669\u201375.","journal-title":"Pharmacotherapy"},{"key":"1641_CR13","first-page":"468","volume":"69","author":"RJ Lau","year":"1987","unstructured":"Lau RJ, Emery MG, Galinsky RE. Unexpected accumulation of acyclovir in breast milk with estimation of infant exposure. Obstet Gynecol. 1987;69:468\u201371.","journal-title":"Obstet Gynecol"},{"key":"1641_CR14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0009-9236(95)90175-2","volume":"58","author":"CY Oo","year":"1995","unstructured":"Oo CY, Kuhn RJ, Desai N, McNamara PJ. Active transport of cimetidine into human milk. Clin Pharmacol Ther. 1995;58:548\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"1641_CR15","unstructured":"Meskin MS, Lien EJ. QSAR analysis of drug excretion into human breast milk. J Clin Hosp Pharm. 1985;10:269\u201378."},{"key":"1641_CR16","doi-asserted-by":"crossref","unstructured":"Agatonovic-Kustrin S, Ling LH, Tham SY, Alany RG. Molecular descriptors that influence the amount of drugs transfer into human breast milk. J Pharm Biomed Anal. 2002;29:103\u201319.","DOI":"10.1016\/S0731-7085(02)00037-7"},{"key":"1641_CR17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.bmc.2004.12.015","volume":"13","author":"AR Katritzky","year":"2005","unstructured":"Katritzky AR, Dobchev DA, Hur E, Fara DC, Karelson M. QSAR treatment of drugs transfer into human breast milk. Bioorg Med Chem. 2005;13:1623\u201332.","journal-title":"Bioorg Med Chem"},{"key":"1641_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11095-005-8716-4","volume":"23","author":"C Zhao","year":"2006","unstructured":"Zhao C, Zhang H, Zhang X, et al. Prediction of milk\/plasma drug concentration (M\/P) ratio using support vector machine (SVM) method. Pharm Res. 2006;23:41\u20138.","journal-title":"Pharm Res"},{"key":"1641_CR19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/0041-008X(90)90039-W","volume":"102","author":"LA Dostal","year":"1990","unstructured":"Dostal LA, Weaver RP, Schwetz BA. Excretion of high concentrations of cimetidine and ranitidine into rat milk and their effects on milk composition and mammary gland nucleic acid content. Toxicol Appl Pharmacol. 1990;102:430\u201342.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1641_CR20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0022-3565(24)29678-6","volume":"296","author":"PM Gerk","year":"2001","unstructured":"Gerk PM, Oo CY, Paxton EW, Moscow JA, McNamara PJ. Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk. J Pharmacol Exp Ther. 2001;296:175\u201380.","journal-title":"J Pharmacol Exp Ther"},{"key":"1641_CR21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0022-3565(25)11164-6","volume":"261","author":"PJ McNamara","year":"1992","unstructured":"McNamara PJ, Burgio D, Yoo SD. Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. J Pharmacol Exp Ther. 1992;261:918\u201323.","journal-title":"J Pharmacol Exp Ther"},{"key":"1641_CR22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nm1186","volume":"11","author":"JW Jonker","year":"2005","unstructured":"Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med. 2005;11:127\u20139.","journal-title":"Nat Med"},{"key":"1641_CR23","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1124\/mol.104.010439","volume":"67","author":"G Merino","year":"2005","unstructured":"Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The breast cancer resistance protein (BCRP\/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005;67:1758\u201364.","journal-title":"Mol Pharmacol"},{"key":"1641_CR24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tips.2005.11.007","volume":"27","author":"AE Herwaarden van","year":"2006","unstructured":"van Herwaarden AE, Schinkel AH. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci. 2006;27:10\u20136.","journal-title":"Trends Pharmacol Sci"},{"key":"1641_CR25","doi-asserted-by":"crossref","unstructured":"Ito N, Ito K, Ikebuchi Y, et al. Organic cation transporter\/solute carrier family 22a is involved in drug transfer into milk in mice. J Pharm Sci. 2014;(in press).","DOI":"10.1002\/jps.24138"},{"key":"1641_CR26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.102.038315","volume":"303","author":"J Alcorn","year":"2002","unstructured":"Alcorn J, Lu X, Moscow JA, McNamara PJ. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther. 2002;303:487\u201396.","journal-title":"J Pharmacol Exp Ther"},{"key":"1641_CR27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1017\/S002202990800335X","volume":"75","author":"C Farke","year":"2008","unstructured":"Farke C, Meyer HH, Bruckmaier RM, Albrecht C. Differential expression of ABC transporters and their regulatory genes during lactation and dry period in bovine mammary tissue. J Dairy Res. 2008;75:406\u201314.","journal-title":"J Dairy Res"},{"key":"1641_CR28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1472-8206.2009.00760.x","volume":"24","author":"SE Gilchrist","year":"2010","unstructured":"Gilchrist SE, Alcorn J. Lactation stage-dependent expression of transporters in rat whole mammary gland and primary mammary epithelial organoids. Fundam Clin Pharmacol. 2010;24:205\u201314.","journal-title":"Fundam Clin Pharmacol"},{"key":"1641_CR29","doi-asserted-by":"crossref","first-page":"E1172","DOI":"10.1152\/ajpendo.00381.2001","volume":"282","author":"DA Groneberg","year":"2002","unstructured":"Groneberg DA, Doring F, Theis S, Nickolaus M, Fischer A, Daniel H. Peptide transport in the mammary gland: expression and distribution of PEPT2 mRNA and protein. Am J Physiol Endocrinol Metab. 2002;282:E1172\u20139.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1641_CR30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0169-409X(03)00031-0","volume":"55","author":"S Ito","year":"2003","unstructured":"Ito S, Alcorn J. Xenobiotic transporter expression and function in the human mammary gland. Adv Drug Deliv Rev. 2003;55:653\u201365.","journal-title":"Adv Drug Deliv Rev"},{"key":"1641_CR31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1124\/dmd.111.040972","volume":"39","author":"H Koshimichi","year":"2011","unstructured":"Koshimichi H, Ito K, Hisaka A, Honma M, Suzuki H. Analysis and prediction of drug transfer into human milk taking into consideration secretion and reuptake clearances across the mammary epithelia. Drug Metab Dispos. 2011;39:2370\u201380.","journal-title":"Drug Metab Dispos"},{"key":"1641_CR32","volume-title":"Medications and mother\u2019s milk","author":"TW Hale","year":"2008","unstructured":"Hale TW. Medications and mother\u2019s milk. 13th ed. TX: Hale Publishing; 2008.","edition":"13"},{"key":"1641_CR33","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1007\/s11095-013-1085-5","volume":"30","author":"N Ito","year":"2013","unstructured":"Ito N, Ito K, Koshimichi H, et al. Contribution of protein binding, lipid partitioning, and asymmetrical transport to drug transfer into milk in mouse versus human. Pharm Res. 2013;30:2410\u201322.","journal-title":"Pharm Res"},{"key":"1641_CR34","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jps.2600770916","volume":"77","author":"HC Atkinson","year":"1988","unstructured":"Atkinson HC, Begg EJ. Relationship between human milk lipid-ultrafiltrate and octanol-water partition coefficients. J Pharm Sci. 1988;77:796\u20138.","journal-title":"J Pharm Sci"},{"key":"1641_CR35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1124\/jpet.111.180398","volume":"339","author":"H Kodaira","year":"2011","unstructured":"Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood\u2013brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther. 2011;339:935\u201344.","journal-title":"J Pharmacol Exp Ther"},{"key":"1641_CR36","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1023\/B:PHAM.0000045245.21637.d4","volume":"21","author":"C Kondo","year":"2004","unstructured":"Kondo C, Suzuki H, Itoda M, et al. Functional analysis of SNPs variants of BCRP\/ABCG2. Pharm Res. 2004;21:1895\u2013903.","journal-title":"Pharm Res"},{"key":"1641_CR37","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1128\/AAC.06345-11","volume":"56","author":"B Barrera","year":"2012","unstructured":"Barrera B, Otero JA, Egido E, et al. The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2\/BCRP. Antimicrob Agents Chemother. 2012;56:3535\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"1641_CR38","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1124\/dmd.106.014274","volume":"35","author":"G Pan","year":"2007","unstructured":"Pan G, Giri N, Elmquist WF. Abcg2\/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos. 2007;35:1165\u201373.","journal-title":"Drug Metab Dispos"},{"key":"1641_CR39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mol.63.1.65","volume":"63","author":"X Wang","year":"2003","unstructured":"Wang X, Furukawa T, Nitanda T, et al. Breast cancer resistance protein (BCRP\/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003;63:65\u201372.","journal-title":"Mol Pharmacol"},{"key":"1641_CR40","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bcp.2010.06.025","volume":"80","author":"SJ Hemauer","year":"2010","unstructured":"Hemauer SJ, Patrikeeva SL, Wang X, et al. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010;80:1080\u20136.","journal-title":"Biochem Pharmacol"},{"key":"1641_CR41","first-page":"779","volume":"31","author":"J Marki-Zay","year":"2013","unstructured":"Marki-Zay J, Tauberne Jakab K, Szeremy P, Krajcsi P. MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013;31:779\u201387.","journal-title":"Clin Exp Rheumatol"},{"key":"1641_CR42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1124\/jpet.104.073916","volume":"312","author":"P Pavek","year":"2005","unstructured":"Pavek P, Merino G, Wagenaar E, et al. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther. 2005;312:144\u201352.","journal-title":"J Pharmacol Exp Ther"},{"key":"1641_CR43","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/dmd.105.008219","volume":"34","author":"G Merino","year":"2006","unstructured":"Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. Breast cancer resistance protein (BCRP\/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006;34:690\u20135.","journal-title":"Drug Metab Dispos"},{"key":"1641_CR44","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.107.014969","volume":"35","author":"T Ando","year":"2007","unstructured":"Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos. 2007;35:1873\u20139.","journal-title":"Drug Metab Dispos"},{"key":"1641_CR45","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1124\/dmd.107.019125","volume":"36","author":"Y Kato","year":"2008","unstructured":"Kato Y, Takahara S, Kato S, et al. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos. 2008;36:1088\u201396.","journal-title":"Drug Metab Dispos"},{"key":"1641_CR46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1139\/y11-045","volume":"89","author":"P Gunness","year":"2011","unstructured":"Gunness P, Aleksa K, Koren G. Acyclovir is a substrate for the human breast cancer resistance protein (BCRP\/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. Can J Physiol Pharmacol. 2011;89:675\u201380.","journal-title":"Can J Physiol Pharmacol"},{"key":"1641_CR47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2005090966","volume":"18","author":"M Hasegawa","year":"2007","unstructured":"Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol. 2007;18:37\u201345.","journal-title":"J Am Soc Nephrol"},{"key":"1641_CR48","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2007.02944.x","volume":"64","author":"HS Kim","year":"2007","unstructured":"Kim HS, Sunwoo YE, Ryu JY, et al. The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol. 2007;64:645\u201354.","journal-title":"Br J Clin Pharmacol"},{"key":"1641_CR49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2013.03.049","volume":"710","author":"H Nakanishi","year":"2013","unstructured":"Nakanishi H, Yonezawa A, Matsubara K, Yano I. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models. Eur J Pharmacol. 2013;710:20\u20138.","journal-title":"Eur J Pharmacol"},{"key":"1641_CR50","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2133\/dmpk.DMPK-11-NT-068","volume":"27","author":"E Beery","year":"2012","unstructured":"Beery E, Rajnai Z, Abonyi T, et al. ABCG2 modulates chlorothiazide permeability\u2013in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27:349\u201353.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1641_CR51","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0022-3476(72)80102-1","volume":"81","author":"MW Werthmann Jr","year":"1972","unstructured":"Werthmann Jr MW, Krees SV. Excretion of chlorothiazide in human breast milk. J Pediatr. 1972;81:781\u20133.","journal-title":"J Pediatr"},{"key":"1641_CR52","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-3476(82)80323-5","volume":"101","author":"ME Miller","year":"1982","unstructured":"Miller ME, Cohn RD, Burghart PH. Hydrochlorothiazide disposition in a mother and her breast-fed infant. J Pediatr. 1982;101:789\u201391.","journal-title":"J Pediatr"},{"key":"1641_CR53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00204-008-0279-9","volume":"82","author":"W Lilienblum","year":"2008","unstructured":"Lilienblum W, Dekant W, Foth H, et al. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH). Arch Toxicol. 2008;82:211\u201336.","journal-title":"Arch Toxicol"},{"key":"1641_CR54","first-page":"53","volume":"7","author":"K Noguchi","year":"2014","unstructured":"Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2\/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med. 2014;7:53\u201364.","journal-title":"Pharmgenomics Pers Med"},{"key":"1641_CR55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1535-7163.MCT-09-0663","volume":"9","author":"JS Lagas","year":"2010","unstructured":"Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010;9:319\u201326.","journal-title":"Mol Cancer Ther"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-015-1641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-015-1641-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-015-1641-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:47:31Z","timestamp":1747669651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-015-1641-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,19]]},"references-count":55,"alternative-id":["1641"],"URL":"https:\/\/doi.org\/10.1007\/s11095-015-1641-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2015,2,19]]}}}